What was the us market valuation of the US precision medicine market in 2024?

The US Market valuation was $7.83 Billion in 2024. Read More

What is the projected market valuation for the US precision medicine market by 2035?

The projected valuation for 2035 is $22.27 Billion. Read More

What is the expected CAGR for the US precision medicine market during the forecast period 2025 - 2035?

The expected CAGR is 9.97% during the forecast period 2025 - 2035. Read More

Which application segment is expected to show the highest growth in the US precision medicine market?

The oncology segment is anticipated to grow from $2.35 Billion to $6.75 Billion. Read More

What are the key technologies driving the US precision medicine market?

Key technologies include genomics, proteomics, and bioinformatics, with genomics projected to grow from $2.5 Billion to $7.5 Billion. Read More

Which end-use segment is projected to have the largest market share in 2035?

Pharmaceutical companies are expected to dominate, growing from $2.35 Billion to $6.75 Billion. Read More

What product category is anticipated to experience significant growth in the US precision medicine market?

Therapeutics is projected to grow from $2.35 Billion to $6.78 Billion. Read More

Who are the leading players in the US precision medicine market?

Key players include Illumina, Thermo Fisher Scientific, and Roche, among others. Read More

What is the growth potential for the infectious diseases segment in the US precision medicine market?

The infectious diseases segment is expected to grow from $1.78 Billion to $4.52 Billion. Read More

How does the us market for genetic testing compare to other product categories in 2035?

Genetic testing is projected to grow from $2.05 Billion to $5.92 Billion, indicating strong demand. Read More

US Precision Medicine Market

US Precision Medicine Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Rare Diseases, Infectious Diseases), By Technology (Genomics, Proteomics, Metabolomics, Microbiomics, Bioinformatics), By End Use (Pharmaceutical Companies, Healthcare Institutions, Research Organizations, Diagnostic Laboratories) and By Product (Diagnostic Tools, Therapeutics, Genetic Testing, Data Analytics Solutions) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

9.97%

2024 Market Size

$ 7.83 Billion

2035 Market Size

$ 22.27 Billion

Pharmaceutical ● Updated May 2026 Report ID: MRFR/Pharma/13135-HCR | Pages: 100 | Author: Vikita Thakur, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Application (USD Billion) | |
  1. 4.1.1 Oncology | |
  2. 4.1.2 Cardiology | |
  3. 4.1.3 Neurology | |
  4. 4.1.4 Rare Diseases | |
  5. 4.1.5 Infectious Diseases |
2. 4.2 Healthcare, BY Technology (USD Billion) | |
  1. 4.2.1 Genomics | |
  2. 4.2.2 Proteomics | |
  3. 4.2.3 Metabolomics | |
  4. 4.2.4 Microbiomics | |
  5. 4.2.5 Bioinformatics |
3. 4.3 Healthcare, BY End Use (USD Billion) | |
  1. 4.3.1 Pharmaceutical Companies | |
  2. 4.3.2 Healthcare Institutions | |
  3. 4.3.3 Research Organizations | |
  4. 4.3.4 Diagnostic Laboratories |
4. 4.4 Healthcare, BY Product (USD Billion) | |
  1. 4.4.1 Diagnostic Tools | |
  2. 4.4.2 Therapeutics | |
  3. 4.4.3 Genetic Testing | |
  4. 4.4.4 Data Analytics Solutions 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Illumina (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Thermo Fisher Scientific (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Abbott Laboratories (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Qiagen (DE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Bristol-Myers Squibb (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 GRAIL (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Foundation Medicine (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Novartis (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY APPLICATION |
6. 6.3 US MARKET ANALYSIS BY TECHNOLOGY |
7. 6.4 US MARKET ANALYSIS BY END USE |
8. 6.5 US MARKET ANALYSIS BY PRODUCT |
9. 6.6 KEY BUYING CRITERIA OF HEALTHCARE |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF HEALTHCARE |
12. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
14. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE |
15. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
16. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
17. 6.14 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE) |
18. 6.15 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion) |
19. 6.16 HEALTHCARE, BY END USE, 2024 (% SHARE) |
20. 6.17 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
21. 6.18 HEALTHCARE, BY PRODUCT, 2024 (% SHARE) |
22. 6.19 HEALTHCARE, BY PRODUCT, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY PRODUCT, 2025-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

US Precision Medicine Market Segmentation

US Precision Medicine Market By Application (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Rare Diseases
Infectious Diseases

US Precision Medicine Market By US Precision Medicine Market (USD Billion, 2025-2035)

Genomics
Proteomics
Metabolomics
Microbiomics
Bioinformatics

US Precision Medicine Market By End Use (USD Billion, 2025-2035)

US Precision Medicine Market Companies
US Precision Medicine Market Institutions
Research Organizations
Diagnostic Laboratories

US Precision Medicine Market By Product (USD Billion, 2025-2035)

Diagnostic Tools
Therapeutics
Genetic Testing
Data Analytics Solutions

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”